ArticleScientific reports2025
Prognostic value of IFI27 in HNSCC and functional analysis under ALKBH5 regulation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to investigate the expression levels and clinical implications of interferon α inducible protein 27 (IFI27) and the N6-methyladenosine (m6A) regulator Alkylation repair homolog 5 (ALKBH5) in head and neck squamous cell carcinoma (HNSCC). We employed bioinformatics methods to analyze the differential expression of IFI27 in HNSCC and its prognostic implications. Additionally, we explored the pathways and mechanisms associated with its enrichment. Immunohistochemistry (IHC) was used to detect the expression of IFI27 protein in HNSCC and adjacent normal tissues. IFI27 expression was significantly up-regulated in HNSCC (P < 0.001), and was correlated with T stage and tumor differentiation degree. The survival curve indicated that patients with high IFI27 expression had shorter overall survival compared to those with low expression. Furthermore, multivariate analysis confirmed that IFI27 expression is an independent prognostic factor in HNSCC patients. IFI27 is involved in the regulation of type I and type III interferon-mediated responses, Retinoic acid-inducible gene I (RIG-I) -like receptor signaling pathways, and biological processes related to innate immune responses. High IFI27 expression is a potential risk factor for the onset and progression of HNSCC. Additionally, the down-regulation of ALKBH5 may enhance IFI27 expression via the RIG-I/IFN-α axis, further influencing the development of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.